Siemens Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Berlin Germany (1847)
Status: No NME R&D (1847)

Organization Overview

First Clinical Trial
2007
NCT00553748
First Marketed Drug
2011
fludeoxyglucose f-18
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

MEDICALI'S | PETNET | Siemens Corporation, Corporate Technology | Siemens Healthcare GmbH | Siemens Healthcare QT | Siemens Healthcare Sp. z o.o. | Siemens Healthineers | Siemens Healthineers AG | Siemens Healthineers, France | Siemens Healthineers Nederland B.V. | Siemens Medical Solutions | Siemens Medical Solutions USA - CSG | Varian, a Siemens Healthineers Company

Active Ingredients

Marketed Drugs (3)

ammonia n-13 (2015)

fludeoxyglucose f-18 (2011)

sodium fluoride (18F) (2015)

Drugs in Phase 3 Trials (1)

Ga 68 PSMA-11 (Illuccix) (1 trial)

Drugs in Phase 2 Trials (5)

cisplatin (platinol) (1 trial)

fluoromisonidazole (1 trial)

hx4 (4 trials)

perfluorobutane (Sonazoid) (1 trial)

rgd-k5 (3 trials)

Drugs in Phase 1 Trials (4)

cp-18 (1 trial)

fluorothymidine (2 trials)

vm4-037 (1 trial)

w372 (1 trial)

Drugs in Other Trials (2)

iobitridol (Xenetix) (1 trial)

regadenoson (lexiscan) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 1)

Brain Neoplasms (Phase 1)

Breast Neoplasms (Phase 2)

Carcinoma (Phase 1)

Carcinoma, Hepatocellular (Phase 1)

Carcinoma, Renal Cell (Phase 1)

Carcinoma, Squamous Cell (Phase 1)

Carotid Stenosis (Phase 2)

Constriction, Pathologic (Phase 2)

Head and Neck Neoplasms (Phase 2)

Hypoxia (Phase 2)

Liver Neoplasms (Phase 2)

Lung Neoplasms (Phase 1)

Melanoma (Phase 1)

Prostatic Neoplasms (Phase 3)

Rectal Neoplasms (Phase 2)

Sarcoma (Phase 1)

Uterine Cervical Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 17
  • # of Trial APIs: 12